Long-term safety and efficacy of continuous intrathecal baclofen

Developmental Medicine and Child Neurology

Volumn 44, Issue 10, 2002, Pages 660-665

  Campbell, William M ^a   Ferrel, Anne ^b   McLaughlin, John F ^c,f   Grant, Gerald A ^c   Loeser, John D ^c   Graubert, Catherine ^d   Bjornson, Kristie ^e  

^a MADIGAN ARMY MEDICAL CENTER   (United States)

^b SEATTLE CHILDREN S RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^d CHRMC   (United States)

^e Spasticity Management Research Coordinator CHRMC ^*  (United States)

^f UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACLOFEN; SPASMOLYTIC AGENT;

ACUTE PANCREATITIS; ADOLESCENT; ADULT; ARTICLE; BACKACHE; BEHAVIOR DISORDER; CAREGIVER; CHILD; CLINICAL ARTICLE; CONSTIPATION; DEATH; DECUBITUS; DISEASE SEVERITY; DRUG EFFICACY; DRUG INFUSION; DRUG SAFETY; DRUG USE; DYSPHAGIA; EDEMA; FEMALE; FOLLOW UP; FUNCTIONAL ASSESSMENT; GASTROINTESTINAL SYMPTOM; HUMAN; INFUSION PUMP; LETHARGY; LONG TERM CARE; MALE; MUSCLE HYPERTONIA; PAIN; PATIENT CARE; PNEUMONIA; PRIORITY JOURNAL; QUADRIPLEGIA; RATING SCALE; SALIVATION DISORDER; SATISFACTION; SEIZURE; SPASTICITY; URINARY DYSFUNCTION;

ADOLESCENT; ADULT; BACLOFEN; CEREBRAL PALSY; CHILD; CHILD, PRESCHOOL; CROSS-SECTIONAL STUDIES; EQUIPMENT FAILURE; FEMALE; HUMANS; INFUSION PUMPS, IMPLANTABLE; LONG-TERM CARE; MALE; MUSCLE SPASTICITY; NEUROLOGIC EXAMINATION; RETROSPECTIVE STUDIES; SPINAL CORD; TREATMENT OUTCOME;

EID: 0036772372     PISSN: 00121622     EISSN: None     Source Type: Journal    
DOI: 10.1017/S0012162201002729     Document Type: Article

References (24)

1. Albright AL, Shultz BL. (1999) Plasma baclofen levels in children receiving continuous intrathecal baclofen infusion. Journal of Child Neurology 14: 408-9.
2. Albright AL. (1996) Intrathecal baclofen in cerebral palsy movement disorders. Journal of Child Neurology 11: (Suppl. 1) S29-S35.
3. Albright AL, Barry MJ, Shafron DH, Ferson SS. (2001) Intrathecal baclofen for generalized dystonia. Developmental Medicine & Child Neurology 43: 652-7.
4. Armstrong RW, Steinbok P, Cochrane DD, Kube SD, Fife SE, Farrell K. (1997) Intrathecally administered baclofen for treatment of children with spasticity of cerebral origin. Journal of Neurosurgery 87: 409-14.
5. Bohannon RW, Smith MB. (1987) Interrater reliability of a modified Ashworth Scale of muscle spasticity. Physical Therapy 67: 206-7.
6. Evans PM, Alberman E. (1990) Certified cause of death in children and young adults with cerebral palsy. Archives of Disease in Childhood 65: 325-7.
7. Gerszten PC, Albright AL, Johnstone GF. (1998) Intrathecal baclofen infusion and subsequent orthopedic surgery in patients with spastic cerebral palsy. Journal of Neurosurgery 88: 1009-13.
8. Gianino JM, York MM, Paice JA, Shott S. (1998) Quality of life: effect of reduced spasticity from intrathecal baclofen. Journal of Neuroscience Nursing 30: 47-54.
9. Gilmartin R, Bruce D, Storrs BB, Abbott R, Krach L, Ward J, Bloom K, Brooks WH, Johnson DL, Madsen JR, McLaughlin JF, Nadell J. (2000) Intrathecal baclofen for management of spastic cerebral palsy: multicenter trial. Journal of Child Neurology 15: 71-7.
10. Green LB, Nelson VS. (1999) Death after acute withdrawal of intrathecal baclofen: case report and literature review. Archives of Physical Medicine and Rehabilitation 80: 1600-4.
11. Haley SM, Coster WJ, Ludlow LH. (1991) Pediatric functional outcome measures. Physical Medicine and Rehabilitation Clinics of North America 2: 689-723.
12. Katz RT, Rymer WZ. (1989) Spastic hypertonia: mechanisms and measurement. Archives of Physical Medicine and Rehabilitation 70: 144-55.
13. Leichtner AM, Banta JV, Etienne N, Schwartz AM, Renshaw TS, Solari LD, Ascione J, Hyams JS. (1991) Pancreatitis following scoliosis surgery in children and young adults. Journal of Pediatric Orthopedics 11: 594-8.
14. Meythaler JM, Guin-Renfroe S, Law C, Grabb P, Hadley MN. (2001) Continuously infused intrathecal baclofen over 12 months for spastic hypertonia in adolescents and adults with cerebral palsy. Archives of Physical Medicine and Rehabilitation 82: 155-61.
15. Middel B, Kuipers-Upmeijer H, Bouma J, Staal M, Oenema D, Postma T, Terpstra S, Stewart R. (1997) Effect of intrathecal baclofen delivered by an implanted programmable pump on health related quality of life in patients with severe spasticity. Journal of Neurology, Neurosurgery, and Psychiatry 63: 204-9.
16. Milla PJ, Jackson ADM. (1977) A controlled trial of baclofen in children with cerebral palsy. Journal of International Medical Research 5: 398-404.
17. Palisano R, Rosenbaum P, Walter S, Russell D, Wood E, Galuppi B. (1997) Development and reliability of a system to classify gross motor function in children with cerebral palsy. Developmental Medicine & Child Neurology 39: 214-23.
18. Penn RD, Kroin JS. (1987) Long-term intrathecal baclofen infusion for treatment of spasticity. Journal of Neurosurgery 66: 181-5.
19. Russell DJ, Rosenbaum PL, Cadman DT, Gowland C, Hardy S, Jarvis S. (1989) The Gross Motor Function Measure: a means to evaluate the effects of physical therapy. Developmental Medicine & Child Neurology 31: 341-52.
20. Spilker B. (1991) Collecting adverse event and adverse reaction data in clinical trials. In: Spilker B, editor. Guide to Clinical Trials. New York: Raven Press. p 196-201.
21. Spilker B, Schoenfelder J. (1991) Adverse events (experiences). In Spilker B, Schoenfelder J, editors. Data Collection Forms in Clinical Trials. New York: Raven Press. p 438.
22. Van Schaeybroeck P, Nuttin B, Lagae L, Schrijvers E, Gorghgraef C, Feys P. (2000) Intrathecal baclofen for intractable cerebral spasticity: a prospective placebo-controlled, double-blind study. Neurosurgery 46: 603-12.
23. Young RR. (1994) Spasticity: a review. Neurology 44: (Suppl. 9) 12-20.
24. Young RR, Delwaide PJ. (1981) Drug therapy: spasticity (second of two parts). New England Journal of Medicine 304: 96-9.